CL2024001364A1 - Inhibidores de pi3k-alfa y métodos para su producción y uso - Google Patents
Inhibidores de pi3k-alfa y métodos para su producción y usoInfo
- Publication number
- CL2024001364A1 CL2024001364A1 CL2024001364A CL2024001364A CL2024001364A1 CL 2024001364 A1 CL2024001364 A1 CL 2024001364A1 CL 2024001364 A CL2024001364 A CL 2024001364A CL 2024001364 A CL2024001364 A CL 2024001364A CL 2024001364 A1 CL2024001364 A1 CL 2024001364A1
- Authority
- CL
- Chile
- Prior art keywords
- production
- methods
- pi3k
- alpha inhibitors
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
- C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
- C07C309/35—Naphthalene sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163263474P | 2021-11-03 | 2021-11-03 | |
| CN2021128533 | 2021-11-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024001364A1 true CL2024001364A1 (es) | 2024-10-25 |
Family
ID=86242193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024001364A CL2024001364A1 (es) | 2021-11-03 | 2024-05-03 | Inhibidores de pi3k-alfa y métodos para su producción y uso |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20260125374A1 (enExample) |
| EP (1) | EP4426314A4 (enExample) |
| JP (1) | JP2024540303A (enExample) |
| KR (1) | KR20240112283A (enExample) |
| CN (1) | CN118401245A (enExample) |
| AU (1) | AU2022381187A1 (enExample) |
| CA (1) | CA3236861A1 (enExample) |
| CL (1) | CL2024001364A1 (enExample) |
| IL (1) | IL312466A (enExample) |
| MX (1) | MX2024005429A (enExample) |
| PE (1) | PE20250676A1 (enExample) |
| TW (1) | TW202334136A (enExample) |
| WO (1) | WO2023081757A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021263914B2 (en) | 2020-04-29 | 2026-07-23 | D.E. Shaw Research, Llc | PI3K-α inhibitors and methods of use thereof |
| WO2024055992A1 (zh) * | 2022-09-14 | 2024-03-21 | 南京再明医药有限公司 | 三环化合物及其应用 |
| JP2025538147A (ja) | 2022-11-02 | 2025-11-26 | ペトラ・ファーマ・コーポレイション | 疾患の治療のためのホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリックポケット及びオルソステリックポケットの標的化 |
| WO2024233256A1 (en) | 2023-05-05 | 2024-11-14 | Eli Lilly And Company | Imlunestrant or salts thereof for use in treating and preventing central nervous system (cns) metastases in subjects having er+ breast cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010007100A1 (en) * | 2008-07-15 | 2010-01-21 | Cellzome Ltd | 7-substituted amino triazoles as pi3k inhibitors |
| JP6472803B2 (ja) * | 2013-09-05 | 2019-02-20 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | トリアゾロピリジン化合物、その組成物及び使用方法 |
| WO2017000277A1 (en) * | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Substituted triazolo bicycliccompounds as pde2 inhibitors |
| EP3931188B1 (en) * | 2019-02-26 | 2023-08-30 | Boehringer Ingelheim International GmbH | New isoindolinone substituted indoles and derivatives as ras inhibitors |
| AU2021263914B2 (en) * | 2020-04-29 | 2026-07-23 | D.E. Shaw Research, Llc | PI3K-α inhibitors and methods of use thereof |
-
2022
- 2022-11-02 TW TW111141786A patent/TW202334136A/zh unknown
- 2022-11-03 PE PE2024001004A patent/PE20250676A1/es unknown
- 2022-11-03 WO PCT/US2022/079221 patent/WO2023081757A1/en not_active Ceased
- 2022-11-03 KR KR1020247018494A patent/KR20240112283A/ko active Pending
- 2022-11-03 AU AU2022381187A patent/AU2022381187A1/en active Pending
- 2022-11-03 CN CN202280082873.4A patent/CN118401245A/zh active Pending
- 2022-11-03 JP JP2024526614A patent/JP2024540303A/ja active Pending
- 2022-11-03 IL IL312466A patent/IL312466A/en unknown
- 2022-11-03 EP EP22891040.2A patent/EP4426314A4/en active Pending
- 2022-11-03 CA CA3236861A patent/CA3236861A1/en active Pending
- 2022-11-03 US US18/706,511 patent/US20260125374A1/en active Pending
- 2022-11-03 MX MX2024005429A patent/MX2024005429A/es unknown
-
2024
- 2024-05-03 CL CL2024001364A patent/CL2024001364A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240112283A (ko) | 2024-07-18 |
| EP4426314A1 (en) | 2024-09-11 |
| IL312466A (en) | 2024-06-01 |
| MX2024005429A (es) | 2024-05-21 |
| CN118401245A (zh) | 2024-07-26 |
| JP2024540303A (ja) | 2024-10-31 |
| EP4426314A4 (en) | 2025-10-01 |
| US20260125374A1 (en) | 2026-05-07 |
| PE20250676A1 (es) | 2025-03-04 |
| CA3236861A1 (en) | 2023-05-11 |
| AU2022381187A1 (en) | 2024-05-16 |
| TW202334136A (zh) | 2023-09-01 |
| WO2023081757A1 (en) | 2023-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020005348A (es) | Formas cristalinas de la n-(4-(4-(ciclopropilmetil)piperazin-1-car bonil)fenil)quinolin-8-sulfonamida. | |
| ECSP21085481A (es) | Pirroles tricíclicos condensados como moduladores de alfa-1 antitripsina | |
| ECSP18092481A (es) | Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos | |
| ECSP19021312A (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad, kits, y métodos | |
| DOP2019000290A (es) | Inhibidores de quinasa y usos de los mismos | |
| MX355428B (es) | Formas cristalinas del acido [ (4-hidroxi-1-metil-7-fenoxi-isoquin olin-3-carbonil) -amino] -acetico inhibidor de prolil hidroxilasa. | |
| CL2019002321A1 (es) | Procesos para preparar ag-10, sus intermediarios, y sales de los mismos. | |
| MX2019014885A (es) | Formas amorfas y cristalinas de inhibidores de indolamina 2,3-dioxigenasa (ido). | |
| MX2019015744A (es) | Composiciones farmaceuticas. | |
| UY36166A (es) | Formas de sales de n—(cianometil)—4—(2—(4—morfolinofenilamino)pirimidin—4—il)benzamida, sus composiciones y su uso terapeutico | |
| AR113803A1 (es) | Compuesto de pirimidina como inhibidor de jak quinasas | |
| UY39517A (es) | Inhibidores de la btk | |
| CO2021010930A2 (es) | Hidroxipiridoxazepinas como activadores de nrf2 | |
| CO2020000371A2 (es) | Intermedios útiles para la síntesis de un inhibidor selectivo contra proteín cinasas y procesos para preparar los mismos | |
| CL2021000844A1 (es) | Compuestos de indolinona para uso como inhibidores de map4k1 | |
| UY39390A (es) | Forma amorfa de un inhibidor de la malt1 y formulaciones del mismo | |
| UY37551A (es) | Activador de nrf2 | |
| CL2021000903A1 (es) | Nhibidores de ror gamma (solicitud divisional de la solicitud 217-2020 | |
| CL2020000190A1 (es) | Inhibidores de ror-gamma. | |
| MX2021003482A (es) | Proceso de elaboracion de alfa-cetoglutarato de calcio referencia cruzada con solicitudes relacionadas. | |
| CL2021001640A1 (es) | Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéuticas del mismo | |
| MX2024005429A (es) | Inhibidores de las fosfatidilinositol 3-cinasas-alfa (pi3k-alfa) y metodos para su produccion y uso. | |
| MX2021000611A (es) | Una sal de xinafoato de un compuesto inhibidor de jak. | |
| CO2024000763A2 (es) | Composiciones y métodos de los anticuerpos anti-pacap | |
| MX2024003693A (es) | Forma cristalina del derivado de imidazolinona. |